Stephen F. Betz, Chief Scientific Officer at Crinetics Pharmaceuticals, Inc. (CRNX), sold 6,000 shares at $32.87 ($197K) on 2023-12-11, disclosed to the SEC on 2023-12-13.
Scheduled sale ($197k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.87 | 3,000 | $99K | 50.0% |
| 2 | $32.87 | 3,000 | $99K | 50.0% |
| Total | $32.87 avg | 6,000 | $197K | 100% |
| Filing → |
| CRNX | SELL | 2025-03-21 | $385K | — | Filing → |
| CRNX | SELL | 2024-09-12 | $107K | — | Filing → |
| CRNX | SELL | 2024-08-28 | $160K | — | Filing → |